On this week’s BioTech Nation, Moira speaks with Dr. Adam Rogers, CEO of NervGen Pharma.
Dr. Adam Rogers spoke with Forbes about NVG-291 and the Phase 1b/2a CONNECT SCI Study.
Dr. Adam Rogers spoke with BioSpace about NVG-291 and the Phase 1b/2a CONNECT SCI Study.
NervGen Pharma Corp (“NervGen”) (NASDAQ: NGEN), is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. NervGen’s lead therapeutic candidate, NVG-291, is a first- and potentially best-in-class subcutaneously administered candidate being evaluated in the Phase 1b/2a CONNECT SCI Study in individuals living with spinal cord injury. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: [email protected]